Alec Stranahan Stock Analyst Profile - B of A Securities Research Coverage - Stocknear

Alec Stranahan

Stock Analyst at B of A Securities

(3.7)
# 2330
Out of 5,506 analysts
38
Total ratings
Success rate
Average return
Main Sectors:

16 Stocks

Name Action PT Current % Upside Ratings Updated
CADL Candel Therapeutics
Downgrades: Neutral
13 7
5.56 25.9% 2 Sep 3, 2025
XNCR Xencor
Downgrades: Neutral
23 12
11.77 1.95% 2 Sep 3, 2025
ERAS Erasca
Downgrades: Underperform
4 1
2.42 -58.68% 3 Sep 3, 2025
NVAX Novavax
Downgrades: Underperform
9 7
9.46 -26% 5 Aug 20, 2025
KRYS Krystal Biotech
Maintains: Buy
193 192
183.36 4.71% 4 Jul 22, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
42 42
25.75 63.11% 1 Mar 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
14 12
n/a n/a 5 Mar 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
28 25
7.95 214.47% 4 Jan 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
13 11
2.27 384.58% 1 Jan 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
24 6
3.66 63.93% 2 Nov 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
13 15
3.92 282.65% 1 Aug 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
48 55
46.71 17.75% 3 Jul 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underperform
5 6
36.7 -83.65% 2 Dec 29, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underperform
60 5
n/a n/a 1 Dec 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
45
n/a n/a 1 Dec 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
58
n/a n/a 1 May 20, 2022